Kevin Smyth - Bio Techne Senior Officer
| TECH Stock | USD 51.62 0.36 0.70% |
Executive
Kevin Smyth is Senior Officer of Bio Techne Corp
| Address | 614 McKinley Place N.E., Minneapolis, MN, United States, 55413 |
| Phone | 612 379 8854 |
| Web | https://www.bio-techne.com |
Bio Techne Management Efficiency
The company has return on total asset (ROA) of 0.063 % which means that it generated a profit of $0.063 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0368 %, meaning that it created $0.0368 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.06. The current Return On Capital Employed is estimated to decrease to 0.04. As of now, Bio Techne's Total Current Assets are increasing as compared to previous years. The Bio Techne's current Intangible Assets is estimated to increase to about 383.9 M, while Non Currrent Assets Other are projected to decrease to under 16.5 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Janet Graesser | Vaxcyte | N/A | |
| Kevin Gray | United Therapeutics | N/A | |
| Julia Madsen | STERIS plc | 60 | |
| Doug Wallace | Legend Biotech Corp | N/A | |
| Sheila Denton | Incyte | 58 | |
| Tim Roberts | Legend Biotech Corp | N/A | |
| Kenneth Kohler | STERIS plc | 62 | |
| Steven MD | Incyte | 58 | |
| Whitney Jones | Vaxcyte | N/A | |
| Deborah Wong | Legend Biotech Corp | N/A | |
| Sherrie Glass | Ascendis Pharma AS | N/A | |
| James JD | Legend Biotech Corp | N/A | |
| Alan Kick | Legend Biotech Corp | N/A | |
| Mark MBA | Vaxcyte | 69 | |
| Mark Mintz | Charles River Laboratories | N/A | |
| Yuhong Qiu | Legend Biotech Corp | N/A | |
| Scott Holmes | Ascendis Pharma AS | N/A | |
| Yong Chung | Bio Rad Laboratories | N/A | |
| Todd Spencer | Charles River Laboratories | N/A | |
| Kennett Sprogoe | Ascendis Pharma AS | 46 | |
| Nyssa Noyola | Ascendis Pharma AS | N/A | |
Management Performance
| Return On Equity | 0.0368 | ||||
| Return On Asset | 0.063 |
Bio Techne Corp Leadership Team
Elected by the shareholders, the Bio Techne's board of directors comprises two types of representatives: Bio Techne inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bio. The board's role is to monitor Bio Techne's management team and ensure that shareholders' interests are well served. Bio Techne's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bio Techne's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynne Hohlfeld, Senior Division | ||
| James Hippel, CFO and VP of Fin. | ||
| Steven Crouse, Senior Division | ||
| Gerry Andros, Vice Marketing | ||
| Bernie Andruss, Senior Division | ||
| Kim Kelderman, Pres Genomics | ||
| Dylan Malayter, Senior Division | ||
| Robert Gavin, Sr. VP of Protein Platforms Division | ||
| Kevin Smyth, Senior Officer | ||
| Gary Latham, VP CTO | ||
| Charles Kummeth, CEO and President and Director | ||
| Brenda Everson, Senior Officer | ||
| Shane Bohnen, General VP | ||
| Luca Cicchetti, Managing Director | ||
| Brenda JD, Gen VP | ||
| James CPA, Executive CFO | ||
| Martin Wirtz, Senior Development | ||
| Cheryl Bethune, Senior Officer | ||
| David CFA, Senior Development | ||
| MD MBA, President Genomics | ||
| Evett Kruka, Senior Division | ||
| David Clair, IR Contact Officer | ||
| William Geist, President Segment | ||
| Steven Silverman, Senior Experience | ||
| Steve Crouse, Senior Division |
Bio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bio Techne a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0368 | ||||
| Return On Asset | 0.063 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.36 % | ||||
| Current Valuation | 8.26 B | ||||
| Shares Outstanding | 155.55 M | ||||
| Shares Owned By Insiders | 1.09 % | ||||
| Shares Owned By Institutions | 98.91 % | ||||
| Number Of Shares Shorted | 5.12 M | ||||
| Price To Earning | 74.38 X |
Currently Active Assets on Macroaxis
| NOAH | Noah Holdings | |
| CIG | Companhia Energetica de | |
| BBVA | Banco Bilbao Viscaya | |
| ENIC | Enel Chile SA | |
| SBSW | Sibanye Gold Ltd |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in consumer price index. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Dividend Share 0.32 | Earnings Share 0.46 | Revenue Per Share | Quarterly Revenue Growth 0.036 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bio Techne's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.